Tagged with NORD

Saudi Arabia Melvin D’Souza outlines the strategy that Novo Nordisk Saudi Arabia – the country’s market leader in diabetes care, obesity, hemophilia, and growth hormone treatment – is following and analyzes the potential impact of local content enhancement for the Kingdom’s Vision 2030 healthcare transformation plans.   The fact that Novo Nordisk…

Denmark Denmark’s four largest pharma companies – Novo Nordisk, Lundbeck, LEO Pharma, and ALK – are all at least partly owned by independent foundations, which means that their profits are divided between their shareholders and the foundations themselves, with funds then channelled into academia and biotech start-ups. Here, a variety of…

Denmark Kenneth Mikkelsen & Jeroen ter Borg describe the work of IQVIA – the world’s biggest CRO and life science data services provider – in Denmark, which has served as a testbed for the rollout of the firm’s healthcare business. Mikkelsen and ter Borg also highlight some of the key market…

Denmark Servier’s Estève Speranza outlines the rationale behind the French group’s reorganisation in the Nordic countries, how the global shift towards oncology is playing out in his region, and the Nordics’ relevance to Servier as an innovation hub and home to its antibody centre of excellence.   Servier is actively looking…

Denmark The BioInnovation Institute (BII) is an initiative from the Novo Nordisk Foundation which aims to support entrepreneurial researchers and early-stage life science start-ups with up to DKK 18 million in founder-friendly funding. CEO Jens Nielsen highlights some of the BII’s milestones and success stories since its formation and Denmark’s progress…

Denmark Kasper Bødker Mejlvang oversees Novo Nordisk’s operations in its historic home market of Denmark, as well as Iceland. Here, Bødker Mejlvang explains his strategy for steering the Danish affiliate through the COVID-19 pandemic, the evolving access landscape for the company’s next-generation diabetes and obesity treatments, and why Denmark – despite…

Global With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why the peptide field is generating so much excitement, outline some of the most significant recent breakthroughs and big-ticket investments, and…

USA The National Organization for Rare Disorders (NORD) is set to host its annual Rare Diseases and Orphan Products Breakthrough Summit on October 18-19th. Ahead of the Summit, the Chair of NORD’s Board of Directors Kay Holcombe explains its significance for cross-stakeholder interaction and learning and why we are entering “a…

China The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, and Sanofi have achieved China growth in the first half of the year despite pricing squeezes on their mature brands; and why Bayer sees huge growth potential…

Turkey Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer to global organisations, why the well-educated and cost-efficient domestic labour force is so important to the Turkish pharma market’s future,…

Global PharmaBoardroom has spread its wings far and wide in 2021 (albeit digitally!), from well covered markets such as Singapore and Switzerland to new frontiers like Saudi Arabia. Our interviewees have ranged from regional Big Pharma and medtech general managers, to the CEOs of important local players, and the heads of…

Singapore Singapore is one of the healthiest countries in Asia with a life expectancy in excess of 82 years buttressed by one of the most robust healthcare apparatuses in the world. “It’s important not to overlook the strengths of this system and just how strong healthcare delivery, affordability and access is…